Morgan Stanley cuts view on Teva in premarket analyst action

|About: Voyager Therapeutics, ... (VYGR)|By:, SA News Editor

Voyager Therapeutics (NASDAQ:VYGR) initiated with Overweight rating and $27 (52% upside) price target at Cantor Fitzgerald.

Mylan N.V. (NASDAQ:MYL) upgraded to Overweight with a $35 (28% upside) price target at Morgan Stanley. Shares up 3% premarket.

Teva Pharmaceutical Industries (NYSE:TEVA) downgraded to Equal Weight with a $17 (2% upside) price target at Morgan Stanley. Shares down 1% premarket.

CVS Health (NYSE:CVS) price target cut to $68 (24% upside) from $94 at Citigroup citing lack of 2020 visibility. Buy rating maintained.

Subscribe for full text news in your inbox